New drug duo aims to spare kidney cancer patients from major surgery
NCT ID NCT05656235
Summary
This study is testing a combination of two drugs, enfortumab vedotin and pembrolizumab, for patients with high-grade cancer in their kidney or ureter who are not candidates for or refuse the standard surgery to remove the organ. The goal is to see if this drug treatment can control the cancer and keep patients free from relapse or death for a similar amount of time as surgery historically has. It is for patients whose cancer has not spread to other parts of the body.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Johns Hopkins University: Sibley Memorial Hospital
RECRUITINGWashington D.C., District of Columbia, 20016, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Johns Hopkins University: Sidney Kimmel Comprehensive Cancer Center
RECRUITINGBaltimore, Maryland, 21287, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.